Aarti Drugs Ltd is Rated Hold by MarketsMOJO

Current Rating Overview and Context

On 17 November 2025, MarketsMOJO adjusted Aarti Drugs Ltd’s rating from 'Buy' to 'Hold', reflecting a change in the company’s overall mojo score which declined by 17 points, from 71 to 54. This shift signals a more cautious stance towards the stock, suggesting that while it remains a viable investment, it no longer meets the criteria for a more aggressive buy recommendation. Investors should understand that a 'Hold' rating indicates the stock is expected to perform in line with the market or sector averages, and may not offer significant upside in the near term.

Here’s How Aarti Drugs Ltd Looks Today

As of 25 December 2025, the stock shows a mixed performance profile. The latest data reveals a one-day gain of 2.81%, with a one-week return of 10.22%. However, over longer periods, the stock has experienced declines, including a 1-month drop of 1.37%, a 3-month fall of 18.00%, and a year-to-date loss of 7.86%. Over the past year, the stock has delivered a negative return of 9.90%, underperforming the BSE500 benchmark consistently over the last three years.

Quality Assessment

The company’s quality grade is assessed as average. Aarti Drugs Ltd demonstrates high management efficiency, reflected in a robust return on capital employed (ROCE) of 15.44%. This indicates that the company is effective at generating profits from its capital base. Additionally, the debt-to-equity ratio remains low at an average of 0.46 times, signalling prudent financial leverage and a manageable debt burden. However, the company’s long-term growth outlook is less encouraging, with operating profit shrinking at an annualised rate of -5.65% over the past five years. This decline in operating profit growth tempers the otherwise positive quality indicators.

Valuation Considerations

Valuation metrics for Aarti Drugs Ltd are currently attractive. The stock trades at a discount relative to its peers’ historical valuations, with an enterprise value to capital employed ratio of 2.2. The company’s ROCE of 12.5 further supports this valuation appeal. Despite the stock’s negative returns over the last year, profits have risen by 30.7%, resulting in a price/earnings to growth (PEG) ratio of 0.6, which suggests undervaluation relative to earnings growth potential. This valuation profile may appeal to investors seeking value opportunities within the pharmaceuticals and biotechnology sector.

Financial Trend Analysis

The financial trend for Aarti Drugs Ltd is positive, supported by recent half-year results. The company reported a profit after tax (PAT) of ₹99.19 crores for the latest six months, marking a strong growth rate of 45.33%. Operating profit to interest coverage ratio reached a high of 10.95 times, indicating solid earnings relative to interest expenses. The debt-equity ratio for the half-year period improved to 0.39 times, the lowest level recorded, underscoring the company’s strengthening balance sheet. Despite these encouraging short-term trends, the longer-term operating profit decline remains a concern for sustained growth.

Technical Outlook

Technically, the stock is rated as sideways, reflecting a lack of clear directional momentum. This sideways trend suggests that the stock price is consolidating within a range, neither exhibiting strong bullish nor bearish signals. Investors relying on technical analysis may interpret this as a period of indecision, recommending a cautious approach until a definitive trend emerges.

Additional Considerations

Promoter confidence in Aarti Drugs Ltd has shown signs of erosion, with promoters reducing their stake by 0.5% in the previous quarter to hold 54.72% currently. This reduction may indicate a tempered outlook from insiders regarding the company’s near-term prospects. Furthermore, the stock’s consistent underperformance against the BSE500 benchmark over the last three years, coupled with negative returns in the past year, highlights challenges in delivering shareholder value relative to the broader market.

What the Hold Rating Means for Investors

For investors, the 'Hold' rating on Aarti Drugs Ltd suggests a balanced view. The company exhibits strengths in management efficiency, valuation attractiveness, and recent financial improvements. However, these positives are tempered by concerns over long-term growth, promoter stake reduction, and technical uncertainty. The rating advises investors to maintain existing positions without adding significant new exposure, while monitoring the company’s progress on growth and market performance. It also implies that investors should consider alternative opportunities if seeking higher growth or momentum stocks within the pharmaceuticals sector.

Summary

In summary, Aarti Drugs Ltd’s current 'Hold' rating reflects a nuanced investment case. The stock offers value through attractive valuation and improving financial metrics, yet faces challenges in sustaining long-term growth and market outperformance. Investors should weigh these factors carefully, recognising that the rating encapsulates the stock’s present fundamentals and market conditions as of 25 December 2025, rather than solely the rating change date of 17 November 2025.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today